Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

Expert Rev Anticancer Ther. 2024 Jul;24(7):481-484. doi: 10.1080/14737140.2024.2354772. Epub 2024 May 13.
No abstract available

Keywords: PD-L1; Recurrent/metastatic head and neck cancer; cetuximab; chemotherapy; combined positive score; pembrolizumab.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Immunological* / administration & dosage
  • Antineoplastic Agents, Immunological* / pharmacology
  • Cetuximab* / administration & dosage
  • Cetuximab* / pharmacology
  • Head and Neck Neoplasms* / drug therapy
  • Head and Neck Neoplasms* / pathology
  • Humans
  • Neoplasm Metastasis*
  • Neoplasm Recurrence, Local* / drug therapy

Substances

  • Cetuximab
  • Antineoplastic Agents, Immunological